估算加纳治疗高血压的终生成本:模型研究。

IF 2.4 Q2 HEALTH CARE SCIENCES & SERVICES Health Services Insights Pub Date : 2024-03-29 eCollection Date: 2024-01-01 DOI:10.1177/11786329241241909
Fidelis Atibila, James Avoka Asamani, Emmanuel Timmy Donkoh, Rob Ruiter, Gerjo Kok, Gill Ten Hoor
{"title":"估算加纳治疗高血压的终生成本:模型研究。","authors":"Fidelis Atibila, James Avoka Asamani, Emmanuel Timmy Donkoh, Rob Ruiter, Gerjo Kok, Gill Ten Hoor","doi":"10.1177/11786329241241909","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Over the last decade, hypertension (HPT) is among the leading causes of death and morbidity in Ghana. In recent past, most health policy research in Ghana and Africa focussed on communicable diseases. In recent times, Ghana and other developing nations have shifted their attention to non-communicable diseases because most of these countries are going through an epidemiologic transition where there is a surge in the prevalence of HPT. This paper was therefore set out to estimate the cost of treating HPT in Ghana from the patients' and health system's perspectives.</p><p><strong>Method: </strong>We used a cost of illness framework to simulate the cost of HPT management in Ghana taking into account 4 of the common target organ complications with the most mortality implication. A decision analytic model (DAM) was developed in Microsoft<sup>®</sup> Excel to simulate the progression of HPT patients and the Markov model was employed in simulating the lifetime cost of illness.</p><p><strong>Results: </strong>The results show that by 10 years from diagnosis, the probability of death from any of the 4 complications (ie, stroke, myocardial infarction, heart failure, and chronic kidney disease) is roughly 41.03%. By 20 years (or 243 months) from diagnosis, the probability of death is estimated to be 69.61%. However, by the 30th anniversary, the probability of death among the cohort is 82.3%. Also, the lifetime discounted cost of treating HPT is about GHS 869 106 which could range between GHS 570 239 and GHS 1.202 million if wide uncertainty is taken into account. This is equivalent to USD 119 056 (range: USD 78 115-164 723).</p><p><strong>Conclusion: </strong>By highlighting the lifetime cost of treating HPT in Ghana, policies can be formulated regarding the cost of treating HPT by the non-communicable disease unit and National Health Insurance Authority (NHIA) of the Ministry of Health.</p>","PeriodicalId":12876,"journal":{"name":"Health Services Insights","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981221/pdf/","citationCount":"0","resultStr":"{\"title\":\"Estimating the Lifetime Cost of Managing Hypertension in Ghana: A Modelling Study.\",\"authors\":\"Fidelis Atibila, James Avoka Asamani, Emmanuel Timmy Donkoh, Rob Ruiter, Gerjo Kok, Gill Ten Hoor\",\"doi\":\"10.1177/11786329241241909\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Over the last decade, hypertension (HPT) is among the leading causes of death and morbidity in Ghana. In recent past, most health policy research in Ghana and Africa focussed on communicable diseases. In recent times, Ghana and other developing nations have shifted their attention to non-communicable diseases because most of these countries are going through an epidemiologic transition where there is a surge in the prevalence of HPT. This paper was therefore set out to estimate the cost of treating HPT in Ghana from the patients' and health system's perspectives.</p><p><strong>Method: </strong>We used a cost of illness framework to simulate the cost of HPT management in Ghana taking into account 4 of the common target organ complications with the most mortality implication. A decision analytic model (DAM) was developed in Microsoft<sup>®</sup> Excel to simulate the progression of HPT patients and the Markov model was employed in simulating the lifetime cost of illness.</p><p><strong>Results: </strong>The results show that by 10 years from diagnosis, the probability of death from any of the 4 complications (ie, stroke, myocardial infarction, heart failure, and chronic kidney disease) is roughly 41.03%. By 20 years (or 243 months) from diagnosis, the probability of death is estimated to be 69.61%. However, by the 30th anniversary, the probability of death among the cohort is 82.3%. Also, the lifetime discounted cost of treating HPT is about GHS 869 106 which could range between GHS 570 239 and GHS 1.202 million if wide uncertainty is taken into account. This is equivalent to USD 119 056 (range: USD 78 115-164 723).</p><p><strong>Conclusion: </strong>By highlighting the lifetime cost of treating HPT in Ghana, policies can be formulated regarding the cost of treating HPT by the non-communicable disease unit and National Health Insurance Authority (NHIA) of the Ministry of Health.</p>\",\"PeriodicalId\":12876,\"journal\":{\"name\":\"Health Services Insights\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-03-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981221/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Services Insights\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11786329241241909\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Services Insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11786329241241909","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

导言:在过去十年中,高血压(HPT)是加纳死亡和发病的主要原因之一。过去,加纳和非洲的大部分卫生政策研究都集中在传染性疾病上。近来,加纳和其他发展中国家已将注意力转移到非传染性疾病上,因为这些国家大多正处于流行病转型期,HPT 的发病率急剧上升。因此,本文旨在从患者和卫生系统的角度估算加纳治疗 HPT 的成本:我们采用疾病成本框架来模拟加纳 HPT 的治疗成本,其中考虑到了死亡率最高的 4 种常见目标器官并发症。我们在 Microsoft® Excel 中开发了一个决策分析模型 (DAM),用于模拟 HPT 患者的病情发展,并采用马尔可夫模型模拟疾病的终生成本:结果显示,确诊后 10 年,死于 4 种并发症(即中风、心肌梗死、心力衰竭和慢性肾病)中任何一种的概率约为 41.03%。到确诊后 20 年(或 243 个月)时,死亡概率估计为 69.61%。然而,到 30 周年时,队列中的死亡概率为 82.3%。此外,治疗 HPT 的终生贴现成本约为 869 106 戈比,如果考虑到广泛的不确定性,则可能在 570 239 至 120.2 万戈比之间。这相当于 119 056 美元(范围:78 115-164 723 美元):通过强调加纳治疗 HPT 的终生成本,卫生部的非传染性疾病部门和国家健康保险管理局 (NHIA) 可以制定有关治疗 HPT 成本的政策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Estimating the Lifetime Cost of Managing Hypertension in Ghana: A Modelling Study.

Introduction: Over the last decade, hypertension (HPT) is among the leading causes of death and morbidity in Ghana. In recent past, most health policy research in Ghana and Africa focussed on communicable diseases. In recent times, Ghana and other developing nations have shifted their attention to non-communicable diseases because most of these countries are going through an epidemiologic transition where there is a surge in the prevalence of HPT. This paper was therefore set out to estimate the cost of treating HPT in Ghana from the patients' and health system's perspectives.

Method: We used a cost of illness framework to simulate the cost of HPT management in Ghana taking into account 4 of the common target organ complications with the most mortality implication. A decision analytic model (DAM) was developed in Microsoft® Excel to simulate the progression of HPT patients and the Markov model was employed in simulating the lifetime cost of illness.

Results: The results show that by 10 years from diagnosis, the probability of death from any of the 4 complications (ie, stroke, myocardial infarction, heart failure, and chronic kidney disease) is roughly 41.03%. By 20 years (or 243 months) from diagnosis, the probability of death is estimated to be 69.61%. However, by the 30th anniversary, the probability of death among the cohort is 82.3%. Also, the lifetime discounted cost of treating HPT is about GHS 869 106 which could range between GHS 570 239 and GHS 1.202 million if wide uncertainty is taken into account. This is equivalent to USD 119 056 (range: USD 78 115-164 723).

Conclusion: By highlighting the lifetime cost of treating HPT in Ghana, policies can be formulated regarding the cost of treating HPT by the non-communicable disease unit and National Health Insurance Authority (NHIA) of the Ministry of Health.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Health Services Insights
Health Services Insights HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.60
自引率
0.00%
发文量
47
审稿时长
8 weeks
期刊最新文献
Corrigendum to "Healthcare Professionals' Resilience during the COVID-19 and Organizational Factors That Improve Individual Resilience: A Mixed-Method Study". A Fuzzy Bi-objective Mathematical Model for Perishable Medical Goods Supply Chain Network Considering Crisis Situations: An Empirical Study. Procedure Prioritization During a Nationwide Ban on Non-Urgent Healthcare: A Quasi-Experimental Retrospective Study of Hospital Data in Switzerland. Navigating Rehabilitation Transitions at Street Level: A Qualitative Analysis of Municipal Service Allocation to Individuals With Complex Needs. Patterns of Antidepressant and Anxiolytic Use and Spending in 14 European Countries (2012-2021): A Comprehensive Time Series Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1